Redeye returns with an update following the CRL and additional consideration, where we lower the lik...
InCoax reported a better-than-expected Q2, with sales and EBITDA ahead of our estimates despite cont...
GFG released H1 figures that confirm the operational inflection anticipated at the FY25 results, wit...
Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.
Yesterday, right after the bell, NFON published weak preliminary Q2/H1 figures alongside a significa...
Yesterday, LION released its Q2 results. Despite a weak quarter performance linked to the preparatio...
Yesterday, Semperit published its H1 financial report, following strong preliminary Q2 figures and i...
DMRE Q2 results arrived slightly ahead of estimates.
Q2 was weak, as already known from the July profit warning, mainly due to several larger US orders b...
* 9% organic growth (cons 2%), adj. EBITA -5% vs cons * 2026 EBITA guidance raised to "significantly...
Q2 net sales and adjusted EBITDA were slightly below our expectations.
Moberg Pharma delivered a strong Q2 2026 report, with sales well ahead of Redeye's forecasts.
Q2's strong operating cash flow was the first clear indication that the efficiency measures are star...
När Entreprenad och Teknik inte levererar, räddar Transport kvartalet med rejäl ökning av omsättning...
Q2 gold production had already been announced in advance in July.
* EBIT was 35% better than ABGSC and 27% vs cons * Order backlog +18% y-o-y, plus major Uppsala tram...
Redeye retains its positive view of Transtema following a Q2 report that beat our expectations somew...
Redeye provides its initial take on Acarix's Q2 report, which came in line with estimates and contai...
Astor's Q2 showed its new scale following the NSG acquisition, while delivery phasing and mix weighe...
Yesterday, INDUS released its H1 26 report. As outlined by preliminary figures published end of July...
